p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma

Correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure

R. Isik, M. Metintas, A. R. Gibbs, S. Metintas, B. Jasani, Ü Öner, E. Harmanci, S. Demircan, S. Iiksoy

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The aim of this study is to investigate immunoreactivity for p53, p21 and metallothionein in diffuse malignant pleural mesothelioma (DMPM) and to determine the relationships between the age, sex, asbestos exposure time, survival of DMPM patients with environmental asbestos exposure and immunoreactivity to p53, p21 and metallothionein. Sixty-seven histopathologically-confirmed DMPMs, 38 of whom had environmental and 29 had occupational asbestos exposure, were included. The tumour tissue samples were immunostained with antibodies against p53, p21 and metallothionein. Epidemiological data and the survival times for the DMPM patients with environmental asbestos exposures were obtained from hospital records. Thirty-three per cent of the DMPMs were positive for p53, 35% for p21 and 52% for metallothionein. There was no statistical difference between the histological subtypes of DMPM in terms of immunoreactivity for p53, p21 and metallothionein. For p21 and metallothionein there was a statistically significant difference between the exposure characteristics: patients with environmental asbestos exposure had shown more immunopositivity. There were statistically significant differences between age groups and between asbestos exposure times for metallothionein, and between asbestos exposure times and p21. The patients with positive immunostaining had longer exposure times and were older than those having negative immunostaining. The differences between survival of the patients were not statistically significant in terms of the immunohistochemical results for p53, p21 and metallothionein.

Original languageEnglish
Pages (from-to)588-593
Number of pages6
JournalRespiratory Medicine
Volume95
Issue number7
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Metallothionein
Asbestos
Mesothelioma
Environmental Exposure
Survival
Malignant Mesothelioma
Hospital Records
Occupational Exposure
Age Groups
Antibodies

Keywords

  • Mesothelioma
  • Metallothionein
  • p21
  • p53
  • Survival

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma : Correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. / Isik, R.; Metintas, M.; Gibbs, A. R.; Metintas, S.; Jasani, B.; Öner, Ü; Harmanci, E.; Demircan, S.; Iiksoy, S.

In: Respiratory Medicine, Vol. 95, No. 7, 2001, p. 588-593.

Research output: Contribution to journalArticle

Isik, R. ; Metintas, M. ; Gibbs, A. R. ; Metintas, S. ; Jasani, B. ; Öner, Ü ; Harmanci, E. ; Demircan, S. ; Iiksoy, S. / p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma : Correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. In: Respiratory Medicine. 2001 ; Vol. 95, No. 7. pp. 588-593.
@article{08f7f1731f6141079e9e8e655dad2cba,
title = "p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: Correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure",
abstract = "The aim of this study is to investigate immunoreactivity for p53, p21 and metallothionein in diffuse malignant pleural mesothelioma (DMPM) and to determine the relationships between the age, sex, asbestos exposure time, survival of DMPM patients with environmental asbestos exposure and immunoreactivity to p53, p21 and metallothionein. Sixty-seven histopathologically-confirmed DMPMs, 38 of whom had environmental and 29 had occupational asbestos exposure, were included. The tumour tissue samples were immunostained with antibodies against p53, p21 and metallothionein. Epidemiological data and the survival times for the DMPM patients with environmental asbestos exposures were obtained from hospital records. Thirty-three per cent of the DMPMs were positive for p53, 35{\%} for p21 and 52{\%} for metallothionein. There was no statistical difference between the histological subtypes of DMPM in terms of immunoreactivity for p53, p21 and metallothionein. For p21 and metallothionein there was a statistically significant difference between the exposure characteristics: patients with environmental asbestos exposure had shown more immunopositivity. There were statistically significant differences between age groups and between asbestos exposure times for metallothionein, and between asbestos exposure times and p21. The patients with positive immunostaining had longer exposure times and were older than those having negative immunostaining. The differences between survival of the patients were not statistically significant in terms of the immunohistochemical results for p53, p21 and metallothionein.",
keywords = "Mesothelioma, Metallothionein, p21, p53, Survival",
author = "R. Isik and M. Metintas and Gibbs, {A. R.} and S. Metintas and B. Jasani and {\"U} {\"O}ner and E. Harmanci and S. Demircan and S. Iiksoy",
year = "2001",
doi = "10.1053/rmed.2001.1108",
language = "English",
volume = "95",
pages = "588--593",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma

T2 - Correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure

AU - Isik, R.

AU - Metintas, M.

AU - Gibbs, A. R.

AU - Metintas, S.

AU - Jasani, B.

AU - Öner, Ü

AU - Harmanci, E.

AU - Demircan, S.

AU - Iiksoy, S.

PY - 2001

Y1 - 2001

N2 - The aim of this study is to investigate immunoreactivity for p53, p21 and metallothionein in diffuse malignant pleural mesothelioma (DMPM) and to determine the relationships between the age, sex, asbestos exposure time, survival of DMPM patients with environmental asbestos exposure and immunoreactivity to p53, p21 and metallothionein. Sixty-seven histopathologically-confirmed DMPMs, 38 of whom had environmental and 29 had occupational asbestos exposure, were included. The tumour tissue samples were immunostained with antibodies against p53, p21 and metallothionein. Epidemiological data and the survival times for the DMPM patients with environmental asbestos exposures were obtained from hospital records. Thirty-three per cent of the DMPMs were positive for p53, 35% for p21 and 52% for metallothionein. There was no statistical difference between the histological subtypes of DMPM in terms of immunoreactivity for p53, p21 and metallothionein. For p21 and metallothionein there was a statistically significant difference between the exposure characteristics: patients with environmental asbestos exposure had shown more immunopositivity. There were statistically significant differences between age groups and between asbestos exposure times for metallothionein, and between asbestos exposure times and p21. The patients with positive immunostaining had longer exposure times and were older than those having negative immunostaining. The differences between survival of the patients were not statistically significant in terms of the immunohistochemical results for p53, p21 and metallothionein.

AB - The aim of this study is to investigate immunoreactivity for p53, p21 and metallothionein in diffuse malignant pleural mesothelioma (DMPM) and to determine the relationships between the age, sex, asbestos exposure time, survival of DMPM patients with environmental asbestos exposure and immunoreactivity to p53, p21 and metallothionein. Sixty-seven histopathologically-confirmed DMPMs, 38 of whom had environmental and 29 had occupational asbestos exposure, were included. The tumour tissue samples were immunostained with antibodies against p53, p21 and metallothionein. Epidemiological data and the survival times for the DMPM patients with environmental asbestos exposures were obtained from hospital records. Thirty-three per cent of the DMPMs were positive for p53, 35% for p21 and 52% for metallothionein. There was no statistical difference between the histological subtypes of DMPM in terms of immunoreactivity for p53, p21 and metallothionein. For p21 and metallothionein there was a statistically significant difference between the exposure characteristics: patients with environmental asbestos exposure had shown more immunopositivity. There were statistically significant differences between age groups and between asbestos exposure times for metallothionein, and between asbestos exposure times and p21. The patients with positive immunostaining had longer exposure times and were older than those having negative immunostaining. The differences between survival of the patients were not statistically significant in terms of the immunohistochemical results for p53, p21 and metallothionein.

KW - Mesothelioma

KW - Metallothionein

KW - p21

KW - p53

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0034933396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034933396&partnerID=8YFLogxK

U2 - 10.1053/rmed.2001.1108

DO - 10.1053/rmed.2001.1108

M3 - Article

VL - 95

SP - 588

EP - 593

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 7

ER -